Identifying nonischemic cardiomyopathy patients who would benefit from an implantable cardioverter-defibrillator: Can late gadolinium enhancement on cardiovascular magnetic resonance imaging help? - 07/02/20
Doi : 10.1016/j.ahj.2019.12.010
Rajat Kalra, MBChB, Chetan Shenoy, MBBS ⁎ 
Cardiovascular Division, Department of Medicine, University of Minnesota Medical Center, Minneapolis, Minnesota, USA
⁎Reprint requests: Chetan Shenoy, MBBS, Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware St SE, MMC 508, Minneapolis, MN 55455.Cardiovascular Division, Department of MedicineUniversity of Minnesota Medical School420 Delaware St SE, MMC 508MinneapolisMN55455
Le texte complet de cet article est disponible en PDF.
© 2019
Elsevier Inc. Tous droits réservés.
Vol 221
P. 177-179 - mars 2020 Retour au numéro
Article précédent
- Consequences of impressive myectomy results in a Center of Excellence: The paradox of evidence-based medicine era
- Josef Veselka
- Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction—The EMMY trial
- Norbert J Tripolt, Ewald Kolesnik, Peter N Pferschy, Nicolas Verheyen, Klemens Ablasser, Sandra Sailer, Hannes Alber, Rudolf Berger, Carl Kaulfersch, Katharina Leitner, Michael Lichtenauer, Arthur Mader, Deddo Moertl, Abderrahim Oulhaj, Christian Reiter, Thomas Rieder, Christoph H. Saely, Jolanta Siller-Matula, Franz Weidinger, Peter M Zechner, Dirk von Lewinski, Harald Sourij, on behalf of the EMMY study group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?